

REFERENCES

- Abramovich CM, Prayson RA, McMahon JT, Cohen BH.** Ultrastructural examination of the axillary skin biopsy in the diagnosis of metabolic diseases. *Hum Pathol* 2001; 32(6): 649–55.
- Ades LC, Gedeon AK, Wilson MJ, et al.** Barth syndrome: clinical features and confirmation of gene localisation to distal Xq28. *Am J Med Genet* 1993; 45(3): 327–34.
- Adwani SS, Whitehead BF, Rees PG, et al.** Heart transplantation for Barth syndrome. *Pediatr Cardiol* 1997; 18(2): 143–5.
- Amendt BA, Rhead WJ.** The multiple acyl-coenzyme A dehydrogenation disorders, glutaric aciduria type II and ethylmalonic– adipic aciduria. Mitochondrial fatty acid oxidation, acyl-coenzyme A dehydrogenase, and electron transfer flavoprotein activities in fibroblasts. *J Clin Invest* 1986; 78(1): 205–13.
- Ammash NM, Seward JB, Bailey KR, et al.** Clinical profile and outcome of idiopathic restrictive cardiomyopathy. *Circulation* 2000; 101: 2490–249.
- Andresen BS, Olpin S, Poorthuis BJ, et al.** Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. *Am J Hum Genet* 1999; 64(2): 479 – 94.
- Andrews RE, Fenton MJ, Ridout DA, Burch M.** New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United Kingdom and Ireland. *Circulation* 2008; 117: 79–84.
- Angelini C.** Defects of fatty-acid oxidation in muscle. *Baillieres Clin Endocrinol Metab* 1990; 4(3): 561 – 82.
- Ansong AK, Li JS, Nozik-Grayck E, et al.** Electrocardiographic response to enzyme replacement therapy for Pompe disease. *Genet Med* 2006; 8(5): 297–301.

References

- Applefeld MM, Wiernik PH.** Cardiac disease after radiation therapy for Hodgkin's disease: analysis of 48 patients. *Am J Cardiol.* Jun 1983; 51(10): 1679-81.
- Arad M, Maron BJ, Gorham JM et al.** Glycogen storage diseases presenting a hypertrophic cardiomyopathy. *N Engl J Med* 2005; 352: 362–372.
- Ardehali H, Qasim A, Cappola T, et al.** Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. *Am Heart J* 2004; 147: 919-923.
- Arola A, Jokinen E, Ruuskanen O, et al.** Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland. *Am J Epidemiol* 1997; 146(5): 385– 93.
- Ausems MG, Lochman P, van Diggelen OP, Ploos van Amstel HK Reuser AJ, Wokke JH.** A diagnostic protocol for adult-onset glycogen storage disease type II. *Neurology* 1999; 52(4): 851– 3.
- Baig MK, Goldman JH, Caforio AL, Coonar AS, Keeling PJ and McKenna WJ.** Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. *J. Am. Coll. Cardiol* 1998; 31: 195–201.
- Banikazemi M, Bultas J, Waldek S, et al.** Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. *Ann Intern Med* 2007; 146(2): 77–86.
- Barth PG, Scholte HR, Berden JA, et al.** An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. *J Neurol Sci* 1983; 62(1– 3): 327– 55.
- Beer G, Reinecke P, Gabbert HE, Hort W, Kuhn H.** Fabry disease in patients with hypertrophic cardiomyopathy (HCM). *Z Kardiol* 2002; 91(12): 992–1002.
- Bell RB, Brownell AK, Roe CR, et al.** Electron transfer flavoprotein: ubiquinone oxidoreductase (ETF:QO) deficiency in an adult. *Neurology* 1990; 40(11): 1779– 82.

References

- Bennett MJ, Allison F, Pollitt RJ, Variend S.** Fatty acid oxidation defects as causes of unexpected death in infancy. *Prog Clin Biol Res* 1990; 321: 349– 64.
- Bennett MJ, Rinaldo P, Millington DS, Tanaka K, Yokota I, Coates PM.** Medium-chain acyl-CoA dehydrogenase deficiency: postmortem diagnosis in a case of sudden infant death and neonatal diagnosis of an affected sibling. *Pediatr Pathol* 1991; 11(6): 889– 95.
- Bernstein D.** Disease of the myocardium and pericardium. In: Kliegman, Bewhrman E, Jenson HB and Santon F (Eds.). *Nelson textbook of pediatrics* 18th ed. (Vol.4): Philadelphia, Saunders Elsevier 2008; 1963-1975.
- Bione S, D'Adamo P, Maestrini E, Gedeon AK, Bolhuis PA, Toniolo D.** A novel X-linked gene, G4.5 is responsible for Barth syndrome. *Nat Genet* 1996; 12(4): 385– 9.
- Bleyl SB, Mumford BR, Thompson V, et al.** Neonatal, lethal noncompaction of the left ventricular myocardium is allelic with Barth syndrome. *Am J Hum Genet* 1997; 61(4): 868–72.
- Bolhuis PA, Hensels GW, Hulsebos TJ, Baas F, Barth PG.** Mapping of the locus for X-linked cardioskeletal myopathy with neutropenia and abnormal mitochondria (Barth syndrome) to Xq28. *Am J Hum Genet* 1991; 48(3): 481–5.
- Bonnet D, Martin D, De Pascale L, et al.** Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. *Circulation* 1999; 100(22): 2248– 53.
- Boucek MM, Edwards LB, Keck BM, Trulock EP, Taylor DO and Hertz MI.** Registry of the International Society for Heart and Lung Transplantation: eighth official pediatric report–2005. *J.Heart Lung Transplant* 2005; 24: 968–982.
- Braunlin EA, Berry JM, Whitley CB.** Cardiac findings after enzyme replacement therapy formucopolysaccharidosis type I. *AmJCardiol* 2006; 98 (3): 416–8.

References

- Braunwald E, Bristow MR.** Congestive heart failure: Fifty years of progress. *Circulation* 2000; 102: 14-23.
- Brockington M, Alsanjari N, Sweeney MG, Morgan-Hughes JA, Scaravilli F, Harding AE.** Kearns–Sayre syndrome associated with mitochondrial DNA deletion or duplication: a molecular genetic and pathological study. *J Neurol Sci* 1995; 131(1): 78–87.
- Brown-Harrison MC, Nada MA, Sprecher H, et al.** Very long chain acyl-CoA dehydrogenase deficiency: successful treatment of acute cardiomyopathy. *Biochem Mol Med* 1996;58(1):59 – 65. *sease.J.Am.Coll. Cardiol* 1998; 31: 195–201.
- Burkett EL and Hershberger RE.** Clinical and genetic issues in familial dilated cardiomyopathy. *J.Am Coll.Cardiol* 2005; 45: 969- 981.
- Cabrera-Salazar MA, Novelli E, Barranger JA.** Gene therapy for the lysosomal storage disorders. *Curr Opin Mol Ther* 2002; 4(4): 349 – 58.
- Cantlay AM, Shokrollahi K, Allen JT, Lunt PW, Newbury-Ecob RA, Steward CG.** Genetic analysis of the G4.5 gene in families with suspected Barth syndrome. *J Pediatr* 1999; 135(3): 311 – 5.
- Chatterjee K and Alpert J.** Constrictive Pericarditis and restrictive cardiomyopathy: similarities and differences. *Heart Fail Monit.* 2003; 3:118–26.
- Chen R, Tsuji T, Ichida F, et al.** Mutation analysis of the G4.5 gene in patients with isolated left ventricular noncompaction. *Mol Genet Metab* 2002; 77(4): 319– 25.
- Chen S, Balfour IC and Jureidini S.** Clinical spectrum of restrictive cardiomyopathy in children. *J. Heart Lung Transplant* 2001; 20: 90–92.
- Chen SC, Balfour IC, Jureidini S.** Clinical spectrum of restrictive cardiomyopathy in children. *J Heart Lung Transplant* 2001; 20: 90–2.
- Chen YT.** Glycogen storage diseases. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, et al, editors. *The metabolic*

References

and molecular bases of inherited disease. New York' McGraw Hil 2001. p. 1521– 51.

Christodoulou J, McInnes RR, Jay V, et al. Barth syndrome: clinical observations and genetic linkage studies. *Am J Med Genet* 1994; 50(3): 255 –64.

Clark BJ. III Treatment of heart failure in infants and children. *Heart Dis* 2000; 2: 354-361.

Cohen N and Muntoni F. Multiple pathogenic mechanisms in x-linked dilated cardiomyopathy. *Heart* 2004; 90: 835-841.

Colan SD and Newburger JW. "Acquired heart disease in children". In "Braunwald Heart Disease: a Textbook of Cardiovascular Medicine". Braunwald E, Zipes DP, Libby P. (eds), 6th edition. Saunders Company. 2001; 1622-1630.

Cook AL, Kishnani PS, Carboni MP, et al. Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha glucosidase enzyme replacement therapy for Pompe disease. *Genet Med* 2006; 8(5): 313–7.

Corr PB, Creer MH, Yamada KA, Saffitz JE, Sobel BE. Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. *J Clin Invest* 1989; 83(3): 927– 36.

Cox GF, Sleeper LA, Lowe AM, et al. Factors associated with establishing a causal diagnosis for children with cardiomyopathy. *Pediatrics* 2006; 118: 1519–31.

Criteria Committee, New York Heart Association, Inc. "Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis". 6th ed. Boston, Little, Brown and Co 1964; 114.

Curcoy A, Olsen RK, Ribes A, et al. Late-onset form of beta-electron transfer flavoprotein deficiency. *Mol Genet Metab* 2003; 78(4): 247–9.

Daubeney PE, Nugent AW, Chondros P et al. Clinical features and outcomes of childhood dilated cardiomyopathy. Results from a

References

- National population based study. *Circulation* 2006; 114: 2671-2678.
- De Lonlay P, Cormier-Daire V, Vuillaumier-Barrot S, et al.** Carbohydrate-deficient blood glycoprotein syndrome. *Arch Pediatr* 2000; 7(2): 173– 84.
- Dec GW and Fuster V.** Medical progress: Idiopathic dilated cardiomyopathy. *N Eng J Med* 1995; 331: 1546-1575.
- Dec GW, Fuster V.** Idiopathic dilated cardiomyopathy. *Med* 1994; 331: 1564-1575.
- Denfield SW, Rosenthal G, Gajarski RJ, et al.** Restrictive cardiomyopathies in childhood. Etiologies and natural history. *Tex Heart Inst J* 1997; 24: 38–44.
- Di Donato S, Frerman FE, Rimoldi M, Rinaldo P, Taroni F, Wiesmann UN.** Systemic carnitine deficiency due to lack of electron transfer flavoprotein:ubiquinone oxidoreductase. *Neurology* 1986; 36(7): 957– 63.
- Egidio RJ, Francis GL, Coates PM, Hale DE, Roesel A.** Medium-chain acyl-CoA dehydrogenase deficiency. *Am Fam Physician* 1989; 39(5): 221– 6.
- Elleder M, Poupetova H, Kozich V.** Fetal pathology in Fabry's disease and mucopolysaccharidosis type I. *Ceskoslov Patol* 1998; 34(1): 7–12.
- Elliot P.** Cardiomyopathy. Diagnosis and management of dilated cardiomyopathy. *Heart* 2000; 84(1): 106-12.
- Eng CM, Guffon N, Wilcox WR, et al.** Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. *N Engl J Med* 2001; 345(1): 9–16.
- Eviatar L, Shanske S, Gauthier B, et al.** Kearns–Sayre syndrome presenting as renal tubular acidosis. *Neurology* 1990; 40(11): 1761–3.

References

- Fairs R, Coats AJ and Henein MY.** Echocardiography derived variables predict outcome in patients with non-ischemic dilated cardiomyopathy with or without a restrictive filling pattern. *Am Heart J* 2002; 144: 343-50.
- Falk RH:** Diagnosis and management of the cardiac amyloidoses. *Circulation* 2005; 112: 2047-2060.
- Feldman BJ, Rosenthal D.** Carbohydrate-deficient glycoprotein syndrome-associated pericardial effusion treated with corticosteroids and salicylic acid. *Pediatr Cardiol* 2002; 23(4): 469– 71.
- Felix SB, Staudt A, Dörffel WV et al.** Hemodynamic effects of immunoabsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. *J Am Coll. Cardiol* 2000; 35 (6): 1590-8.
- Felker GM, Thompson RE, Hare JM, et al.** Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. *N Engl J Med* 2000; 342: 1077-1084.
- Fenton MJ, Chubb H, McMahon AM, Rees P, Elliott MJ and Burch M.** Heart and heart-lung transplantation for idiopathic restrictive cardiomyopathy in children. *Heart* 2006; 92: 85-89.
- Franklin OM and Burch M.** Dilated cardiomyopathy images. *Pediatr Cardiol* 2000; 2: 3-10.
- Garcia Silva MT, de Castro J, Stibler H, et al.** Prenatal hypertrophic cardiomyopathy and pericardial effusion in carbohydrate-deficient glycoprotein syndrome. *J Inherit Metab Dis* 1996; 19(2): 2579.
- Garguilo CE, Stulsatz-Krouper SM, Schaffer JE.** Localization of adipocyte long-chain fatty acyl-CoA synthase at the plasma membrane. *J Lipid Res* 1999; 40: 881– 92.
- Gatzoulis MA, Vellodi A, Redington AN.** Cardiac involvement in mucopolysaccharidoses: effects of allogeneic bone marrow transplantation. *Arch DisChild* 1995; 73(3): 259–60.

References

- Gehrmann J, Sohlbach K, Linnebank M, et al.** Cardiomyopathy in congenital disorders of glycosylation. *Cardiol Young* 2003; 13(4): 345– 51.
- Gerbitz KD, Obermaier-Kusser B, Lestienne P, et al.** Mutations of the mitochondrial DNA: the contribution of DNA techniques to the diagnosis of mitochondrial encephalomyopathies. *J Clin Chem ClinBiochem* 1990; 28(4): 241 –50.
- Gerecht N, Itskovitz SH and Eldor BE.** Human embryonic stem cell: a potential source for cellular therapy *Am J Transplant* 2004; 4 (Suppl): 6:51-57.
- Goldestien JA.** Cardiac tamponade, constrictive Pericarditis and restrictive cardiomyopathy. *Curr. Probl. Cardiol.* 2004; 29: 503-567.
- Goodman SI, Frerman FE.** Glutaric acidemia type II (multiple acyl-CoA dehydrogenation deficiency). *J Inherit Metab Dis* 1984; 7(Suppl.1): 33– 7.
- Goswami VJ. (2008):** Cardiomyopathy restrictive. <http://emedicine.medscape.com/articale/153062>. visited in 2/9/2009.
- Gregersen N, Winter V, Jensen PK, et al.** Prenatal diagnosis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in a family with a previous fatal case of sudden unexpected death in childhood. *Prenat Diagn* 1995; 15(1): 82 –6.
- Grenier MA, Osganian SK, Cox GF, et al.** Design and implementation of the North American Pediatric Cardiomyopathy Registry. *Am Heart J* 2000; 139: S86– 95.
- Gullestad L, Aass H, Fjeld JG et al.** Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. *Circulation* 2001; 103(2): 220-5.
- Ha JW, Ommen SR, Tajik AJ, et al.** Differentiation of constrictive pericarditis from restrictive cardiomyopathy using mitral annular velocity by tissue Doppler echocardiography. *Am J Cardiol* 2004; 94: 316-319.
- Harding AE, Holt IJ.** Mitochondrial myopathies. *Br Med Bu* 1989; 45(3): 760–71.

References

- Hare JM.** The etiologic basis of congestive heart failure. In: Colucci WS, ed. *Atlas of Heart Failure*, Philadelphia: Current Medicine LLC; 2005: 34-58.
- Harmatz P, Giugliani R, Schwartz I, et al.** Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. *J Pediatr* 2006; 148(4): 533–9.
- Harmatz P, Ketteridge D, Giugliani R, et al.** Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux–Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. *Pediatrics* 2005; 115(6): 681–9.
- Harpey JP, Charpentier C, Paturneau-Jouas M.** Sudden infant death syndrome and inherited disorders of fatty acid beta-oxidation. *Biol Neonate* 1990; 58(Suppl. 1): 70–80.
- Hatch GM.** Cell biology of cardiac mitochondrial phospholipids. *Biochem Cell Biol* 2004; 82(1): 99–112.
- Hayashi T, Tsuda E, Kurosaki K, Ueda H, Yamada O and Echigo S.** Electrocardiographic and clinical characteristics of idiopathic restrictive cardiomyopathy in children. *Cir. J.* 2007; 71: 1534-1539.
- Herskhovitz E, Young E, Rainer J, et al.** Bone marrow transplantation for Maroteaux –Lamy syndrome (MPS VI): long-term follow-up. *J Inherit Metab Dis* 1999; 22(1): 50 – 62.
- Hintz SR, Matern D, Strauss A, et al.** Early neonatal diagnosis of long-chain 3-hydroxyacyl coenzyme A dehydrogenase and mitochondrial trifunctional protein deficiencies. *Mol Genet Metab* 2002; 75(2): 120– 7.
- Holt IJ, Harding AE, Cooper JM, et al.** Mitochondrial myopathies: clinical and biochemical features of 30 patients with major

References

- deletions of muscle mitochondrial DNA. *Ann Neurol* 1989; 26(6): 699–708.
- Holt IJ, Harding AE, Morgan-Hughes JA.** Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. *Nature* 1988; 331(6158): 717–9.
- Hoogerbrugge PM, Brouwer OF, Bordigoni P, et al.** Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. *Lancet* 1995; 345(8962): 1398–402.
- Hoogerbrugge PM, Valerio D.** Bone marrow transplantation and gene therapy for lysosomal storage diseases. *Bone Marrow Transplant* 1998; 21(Suppl. 2): S34–6.
- Horvath J, Ketelsen UP, Geibel-Zehender A, et al.** Identification of novel LAMP2 mutation responsible for X-chromosomal dominant Danon disease. *Neuropediatrics* 2003; 34(5): 270–3.
- Hug G.** Glycogen storage diseases. *Birth Defects Orig Artic Ser* 1976; 12(6): 145–75.
- Hughes SE and McKenna WJ.** New insights to the pathology of inherited cardiomyopathy. *Heart* 2005; 91: 257-264.
- Hughes SE.** The pathology of hypertrophic cardiomyopathy. *Histopathology* 2004; 44: 412-27.
- Ino T, Sherwood WG, Benson LN, Wilson GJ, Freedom RM, Rowe RD.** Cardiac manifestations in disorders of fat and carnitine metabolism in infancy. *J Am Coll Cardiol* 1988; 11: 1301-8.
- Kadish A.** Prophylactic defibrillators implantation an evidence-based approach. *N. Engl. J. Med.* 2005; 352: 285-287.
- Kakkis ED, Muenzer J, Tiller GE, et al.** Enzyme-replacement therapy in mucopolysaccharidosis I. *N Engl J Med* 2001; 344(3): 182–8.

References

- Kaneda D, Sugie K, Yamamoto A, et al.** A novel form of autophagi vacuolar myopathy with late-onset and multiorgan involvemen Neurology 2003; 61(1): 128– 31.
- Kay JD, Colan SD and Graham Jr TP.** Imaging and diagnostic testing. Congestive heart failure in pediatric patients. American Heart Journal 2001; 142 (5): 923-8.
- Kemp PM, Little BB, Bost RO, Dawson DB.** Whole blood levels of dodecanoic acid, a routinely detectable forensic marker for a genetic disease often misdiagnosed as sudden infant death syndrome (SIDS):MCAD deficiency. Am J Forensic Med Pathol 1996; 17(1): 79 – 82.
- Kimberling MT, Balzer DT, Hirsch R, et al.** Cardiac transplantation for pediatric restrictive cardiomyopathy: presentation, evaluation, and short-term outcome. J Heart Lung Transplant 2002; 21: 455–9.
- Kishnani PS, Corzo D, Nicolino M, et al.** Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.Neurology 2007; 68(2): 99–109.
- Kishnani PS, Howell RR.** Pompe disease in infants and children. J Pediatr 2004; 144(5 Suppl): S35–43.
- Kishnani PS, Steiner RD, Bali D, et al.** Pompe disease diagnosis and management guideline. Genet Med 2006; 8(5): 267–88
- Klein AL, Cohen GI, Pietrolungo JF, et al.** Differentiation of constrictive pericarditis from restrictive cardiomyopathy by Doppler transesophageal echocardiographic measurements of respiratory variations in pulmonary venous flow. J Am Coll Cardiol. Dec 1993; 22(7): 1935-43.
- Klein AL, Hatle LK, Burstow DJ, et al.** Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. Apr 1989; 13(5): 1017-26.
- Koelling TM, Aarson KD, Cody RJ et al.** Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J 2002; 144(3): 524-9.

References

- Kothari SS, Sharma M.** L-carnitine in children with idiopathic dilated cardiomyopathy. *Indian Heart J* 1998; 50: 59-61.
- Kusa J, Pyrkosz A, Skiba A, Szkutnik M.** Cardiac manifestations of carbohydrate-deficient glycoprotein syndrome. *Pediatr Cardiol* 2003; 24(5): 493– 4.
- Kushwaha SS, Fallon JT, Fuster V.** Restrictive cardiomyopathy. *N Engl J Med*. Jan 23 1997; 336(4): 267-76.
- Lamont PJ, Surtees R, Woodward CE, Leonard JV, Wood NW, Harding AE.** Clinical and laboratory findings in referrals for mitochondrial DNA analysis. *Arch Dis Child* 1998; 79(1): 22 – 7.
- Laschi R, Govoni E, Cenacchi G, Magnani B, Binetti G, Tartagni F.** Primary metabolic cardiomyopathy mimicking an ischemic heart disease. *Ultrastruct Pathol* 1986; 10(5): 387– 94.
- Lee AG, Brazis PW.** Chronic progressive external ophthalmoplegia. *Curr Neurol Neurosci Rep* 2002; 2(5): 413– 7.
- Lestienne P, Ponsot G.** Kearns–Sayre syndrome with muscle mitochondrial DNA deletion. *Lancet* 1988; 1(8590):885.
- Lev D, Nissenkorn A, Leshinsky-Silver E, et al.** Clinical presentations of mitochondrial cardiomyopathies. *Pediatr Cardiol* 2004; 5: 443– 50.
- Levy WC, Mozaffarian D, Linker DT, et al.** The Seattle heart failure model—Prediction of survival in heart failure. *Circulation* 2006; 113: 1424-1433.
- Lewis AB.** Clinical profile and outcome of restrictive cardiomyopathy in children. *Am Heart J* 1992; 123: 1589–93.
- Leya FS, Arab D, Joyal D, et al.** The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. *J Am Coll Cardiol* 2005; 45: 1900-1902.
- Lipshultz SE, Sleeper LA, Towbin JA, et al.** The incidence of pediatric cardiomyopathy in two regions of the United States. *N Engl J Med* 2003; 348(17): 1647 –55.

References

- MacRae CA and Ellinor PT.** Genetic screening and risk assessment in hypertrophic cardiomyopathy .J. Am. Coll. Cardiol. 2004; 44:2326-2328.
- Mandel H, Africk D, Blitzer M, Shapira E.** The importance of recognizing secondary carnitine deficiency in organic acidaemias: case report in glutaric acidaemia type II. J Inherit Metab Dis1988; 11(4): 397 – 402.
- Mann DL, Bristow MR.** Mechanisms and models in heart failure: The biomechanical model and Circulation 2005; 111: 2837-2849.
- Marin-Garcia J, Goldenthal MJ, Filiano JJ.** Cardiomyopathy associated with neurologic disorders and mitochondrial phenotype. J Child Neurol 2002; 17(10): 759–65.
- Maron BJ, Towbin JA, Thiene G, et al.** Contemporary definitions and classification of the cardiomyopathies—An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113: 1807-1816.
- Maron BJ.** Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287: 1308–20.
- Marsac C, Degoul F, Bonne G, et al.** Mitochondrial function and mitochondrial DNA in a series of 64 patients suspected of having mitochondrial myopathy. Rev Neurol (Paris) 1991; 147(6– 7): 462– 6.
- Matern D, Strauss AW, Hillman SL, Mayatepek E, Millington DS, Trefz FK.** Diagnosis of mitochondrial trifunctional protein deficiency in a blood spot from the newborn screening card by tandem mass spectrometry and DNA analysis. Pediatr Res 1999; 46(1): 45– 9.
- McKenna W, Deanfield J, Faruqui A, England D, Oakley C, Goodwin J.** Prognosis in hypertrophic cardiomyopathy: role of

References

- age and clinical, electrocardiographic and hemodynamic features. *Am J Cardiol* 1981; 47:532–8.
- McMahon CJ, Nagueh SF, Eapen RS et al.** Echocardiographic predictors of adverse clinical events in children with dilated cardiomyopathy: a prospective clinical study. *Heart* 2004 ; 90(8):908-915.
- McMillin JB, Dowhan W.** Cardiolipin and apoptosis. *Biochim Biophys Acta* 2002; 1585(2–3): 97– 107.
- McNamara DM, Holubkov R, Starling RC et al.** Controlled trial of intravenous immunoglobulin in recent-onset dilated cardiomyopathy. *Circulation* 2001; 103(18): 2254-9.
- McNamara DM, MacGowan GA and London B.** Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease. *Am. J. Pharmacogenomics* 2002; 2: 73–78.
- Miller S, Riessen R.** [MR imaging in cardiomyopathies]. *Rofo*. Nov 2005; 177(11): 1497-505.
- Morita H.** Gene therapy for cardiomyopathy. *Nippon. Rinsho* 2001; 59(1): 137-40.
- Muenzer J.** The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. *J Pediatr* 2004; 144(5 Suppl): S27–34.
- Muenzer J, Wraith JE, Beck M, et al.** A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). *Genet Med* 2006; 8(8): 465–73.
- Murphy RS and Starling MC.** Genetics and cardiomyopathy: Where are now. *Cleveland Clinical Journal of Medicine* 2005; 72(6): 465-483.
- Nada MA, Vianey-Saban C, Roe CR, et al.** Prenatal diagnosis of mitochondrial fatty acid oxidation defects. *Prenat Diagn* 1996; 16(2): 117– 24.

References

- Nambu M, Kawabe K, Fukuda T, et al.** A neonatal form of glycogen storage disease type IV. *Neurology* 2003; 61(3): 392–4.
- Natowicz MR, Prencz EM.** Heterozygote screening for Tay–Sachs disease: past successes and future challenges. *Curr Opin Pediatr* 1996; 8(6): 625–9.
- Neufeld E, Muenzer J.** The mucopolysaccharidoses. In: Scriver C, Beaudet A, Sly W, Valle D, editors. *The Metabolic and Molecular Bases of Inherited Disease*. New York: McGraw-Hill; 2001. p. 3421–52.
- Nugent AW, Daubeney PEF, Chondros P, et al.** The epidemiology of childhood cardiomyopathy in Australia. *N Engl J Med* 2003; 348(17): 1639–46.
- Oechslin EN, Attenhofer Jost CH, Rojas JR, Kaufmann PA and Jenni R.** Long term follow up of 34 adults with isolated left ventricular non compaction: A distinct cardiomyopathy with poor prognosis. *Am Col. Cardiol* 2000; 36: 493
- Olson TM and Chan DP.** Dilated congestive cardiomyopathy .In Moss and Adms *Heart Diseases In Infants, Children, and Adolescent Including the Fetus and Young Adults*. Allen HD, Gutgesell HP, Clark EB et al., (Eds). 6th Edition. Lippincott Williams & Wilins. 2001; 1187-1196.
- Ota Y, Awaya S, Tanaka M, et al.** Detection of deletions in platelet mitochondrial DNA in Kearns–Sayre syndrome using polymerase chain reaction. *Nippon Ganka Gakkai Zasshi* 1991; 95(8):776– 82.
- Owan TE, Hodge DO, Herges RM, et al.** Trends in prevalence and outcome of heart failure with preserved ejection fraction. *N Engl J Med* 2006; 355: 251-259.
- Peddy SB, Vricella LA, Crosson JE et al.** Infantile Restrictive Cardiomyopathy Resulting From a Mutation in the Cardiac Troponin T Gene. *Pediatrics* 2006; 117 (5):1830-1833
- Pereira A, Martins E, Carvalho C, Alvares S.** Cardiac involvement in metabolic diseases. *Rev Port Cardiol* 1999; 18(1): 53– 7.

References

- Purevjav E, Kimura M, Takusa Y, et al.** Molecular study of electron transfer flavoprotein alpha-subunit deficiency in two Japanese children with different phenotypes of glutaric acidemia type II. *Eur J Clin Invest* 2002; 32(9): 707–12.
- Rahman JE, Helou EF, Gelzer-Bell R, et al.** Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. *J Am Coll Cardiol* 2004; 43: 410-415.
- Richardson P, McKenna W, Bristow M, et al.** Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. *Circulation* 1996; 93: 841–2.
- Rinaldo P, Matern D, Bennett MJ.** Fatty acid oxidation disorders. *Annu Rev Physiol* 2002; 64: 477–502.
- Rivenes SM, Kearney DL, Smith EO, et al.** Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy. *Circulation* 2000; 102: 876–82.
- Roberts R and Sigwart U.** New concepts in hypertrophic cardiomyopathies, part II *Circulation* 2001; 104:2249-52.
- Rochitte CE, Tassi EM, Shiozaki AA.** The emerging role of MRI in the diagnosis and management of cardiomyopathies. *Curr Cardiol Rep.* Feb 2006; 8(1): 44-52.
- Ronghe MD, Foot AB, Martin R, Ashworth M, Steward CG.** Non-Epstein–Barr virus-associated T-cell lymphoma following cardiac transplantation for Barth syndrome. *Acta Paediatr* 2001; 90(5): 584–6.
- Rosenthal D, Chrisant MR, Edens E et al.** International Society for Heart and Lung Transplantation: Practice guidelines for management for heart failure in children. *J. Heart Lung Transplant* 2004; 23:1313-1333.
- Russo LM and Webber SA.** Idiopathic restrictive cardiomyopathy in children. *Heart* 2005; 91: 1199-1202
-

References

- Rutakingirwa M, Ziegler JL, Newton R, et al.** Poverty and eosinophilia are risk factors for endomyocardial fibrosis (EMF) in Uganda. *Trop Med Internat Health* 1999; 4: 229-235.
- Sachdev B, Takenaka T, Teraguchi H et al.** Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. *Circulation* 2002; 105: 1407–1411.
- Scaglia F, Scheuerle AE, Towbin JA, Armstrong DL, Sweetman L, Wong LJ.** Neonatal presentation of ventricular tachycardia and a Reye-like syndrome episode associated with disturbed mitochondrial energy metabolism. *BMC Pediatr* 2002; 2(1): 12.
- Schmiedel J, Jackson S, Schafer J, Reichmann H.** Mitochondrial cytopathies. *J Neurol* 2003; 250(3): 267–77.
- Schon EA, Rizzuto R, Moraes CT, Nakase H, Zeviani M, DiMauro S.** A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. *Science* 1989; 244(4902): 346– 9.
- Schwartz ML, Cox GF, Lin AE, et al.** Clinical approach to genetic cardiomyopathy in children. *Circulation* 1996; 94(8): 2021– 38.
- Seth S, Thatai D, Sharma S, et al.** Clinico-pathological evaluation of restrictive cardiomyopathy (endomyocardial fibrosis and idiopathic restrictive cardiomyopathy) in India. *Euro J Heart Fail* 2004; 6: 723-729.
- Shah JS, Elliott PM.** Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy. *Acta Paediatr Suppl* 2005; 94(447): 11–4.
- Shepler SA and Patel AN.** Cardiac cell therapy: a treatment option for cardiomyopathy. *Crit. Care.* 2007; 30(1):74-80.
- Shoffner JM, Lott MT, Voljavec AS, Soueidan SA, Costigan DA,Wallace DC.** Spontaneous Kearns–Sayre/chronic external ophthalmoplegia plus syndrome associated with a mitochondrial DNA deletion: a slip-replication model and metabolic therapy. *Proc Natl Acad Sci U S A* 1989; 86(20): 7952– 6.

References

- Sims HF, Brackett JC, Powell CK, et al.** The molecular basis of pediatric long chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. *Proc Natl Acad Sci U S A* 1995; 92(3): 841– 5.
- Slukvin II, Salamat MS, Chandra S.** Morphologic studies of the placenta and autopsy findings in neonatal-onset glutaric academia type II. *Pediatr Dev Pathol* 2002; 5(3): 315– 21.
- Sota Rodriguez JE and Cortina JM.** Early results with partial left ventriculectomy (the Batista operation) *Rev Esp Cardiol.* 2000; 1022-1027ISSN 1579-2242
- Spevak P.** Myocardial disease in fetal, neonatal and infant cardiac disease. In: Moller JH, Neal WA, editors. Stamford (CT): Appelton & Lange; 1990.
- Spiekerkoetter U, Sun B, Khuchua Z, Bennett MJ, Strauss AW.** Molecular and phenotypic heterogeneity in mitochondrial trifunctional protein deficiency due to beta-subunit mutations. *Hum Mutat* 2003; 21(6): 598– 607.
- Spinelli L, Pisani A, Sabbatini M, et al.** Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. *Clin Genet* 2004; 66(2): 158–65.
- Stocum M.** stem cell in CNS and Cardiac regeneration *Adv-Biochem* 2005; 93: 135-59.
- Strauss A, Lock JE.** Pediatric cardiomyopathy—a long way to go. *N Engl J Med* 2003; 348(17): 1703–5.
- Schwartz ML, Cox GF, Lin AE, et al.** Clinical approach to genetic cardiomyopathy in children. *Circulation* 1996; 94(8): 2021– 38.
- Strauss AW, Powell CK, Hale DE, et al.** Molecular basis of human mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood. *Proc Natl Acad Sci U S A* 1995; 92(23): 10496–500.

References

- Tay SK, Akman HO, Chung WK, et al.** Fatal infantile neuromuscular presentation of glycogen storage disease type IV. *Neuromuscul Disord* 2004; 14(4): 253– 60.
- Teuteberg JJ, Lewis EF, Nohria A, et al.** Characteristics of patients who die with heart failure and a low ejection fraction in the new millennium. *J Cardiac Fail* 2006; 12: 47-53.
- Thiene G, Corrado D, Basso C.** Cardiomyopathies: is it time for a molecular classification, *Eur Heart J* 2004; 25: 1772-1775.
- Thurberg BL, Rennke H, Colvin RB, et al.** Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. *Kidney Int* 2002; 62(6): 1933–46.
- Tjang YS, Blanz U, Hornik L et al.** Heart transplantation in children: clinical outcomes In a Single center. *Ann. Thorac. Surg* 2007; 84(4): 1640-4.
- Torpy JM, Lynm C and Glass RM.** Heart disease, cardiomyopathy. *JAMA* 2004; 292: 2936.
- Touma EH, Charpentier C.** Medium chain acyl-CoA dehydrogenase deficiency. *Arch Dis Child* 1992; 67(1): 142– 5.
- Touma EH, Rashed MS, Vianey-Saban C, et al.** A severe genotype with favourable outcome in very long chain acyl-CoA dehydrogenase deficiency. *Arch Dis Child* 2001; 84(1): 58 – 60.
- Towbin JA, Lowe AM, Colan SD et al.** Incidence, causes, and outcomes of dilated cardiomyopathy in children. *JAMA* 2006; 296 (15): 1867-1876.
- Tranchant C, Mousson B, Mohr M, et al.** Cardiac transplantation in an incomplete Kearns–Sayre syndrome with mitochondrial DNA deletion. *Neuromuscul Disord* 1993; 3(5– 6): 561–6.
- Treem WR.** New developments in the pathophysiology, clinical spectrum, and diagnosis of disorders of fatty acid oxidation. *Curr Opin Pediatr* 2000; 12(5): 463– 8.

References

- Tripp ME, Shug AL.** Plasma carnitine concentrations in cardiomyopathy patients. *Biochem Med* 1984; 32: 199-206.
- Tsirka AE, Trinkaus K, Chen SC *et al.*** Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. *J. Am. Coll. Cardiol.* 2004; 44:391-397.
- Tulinius MH, Holme E, Kristiansson B, Larsson NG, Oldfors A.** Mitochondrial encephalomyopathies in childhood: II. Clinical manifestations and syndromes. *J Pediatr* 1991; 119(2): 251– 9.
- Valantine HA, Appleton CP, Hatle LK, *et al.*** A hemodynamic and Doppler echocardiographic study of ventricular function in long-term cardiac allograft recipients. Etiology and prognosis of restrictive-constrictive physiology. *Circulation.* Jan 1989; 79(1): 66-75.
- Valianpour F, Wanders RJ, Overmars H, *et al.*** Cardiolipin deficiency in X-linked cardioskeletal myopathy and neutropenia (Barth syndrome, MIM 302060): a study in cultured skin fibroblasts. *J Pediatr* 2002; 141(5): 729–33.
- Van den Hout H, Reuser AJ, Vulto AG, LoonenMC, Cromme-Dijkhuis A, Van der Ploeg AT.** Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. *Lancet* 2000; 356(9227): 397–8.
- Veinot JP.** Diagnostic endomyocardial biopsy pathology: secondary myocardial disease and other clinical indication. *Can. J. Cardiol.* 2002; 18 (3): 287-96.
- Vianey-Saban C, Divry P, Brivet M, *et al.*** Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency: clinical characteristics and diagnostic considerations in 30 patients. *Clin Chim Acta* 1998; 269(1): 43– 62.
- Vinallonga X, Sanz N, Balaguer A, Miro L, Ortega JJ, Casaldaliga J.** Hypertrophic cardiomyopathy in mucopolysaccharidoses: regression after bone marrow transplantation. *Pediatr Cardiol* 1992; 13(2): 107–9.
- Vreken P, Valianpour F, Nijtmans LG, *et al.*** Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndrome. *Biochem Biophys Res Commun* 2000; 279(2): 378– 82.

References

- Wallace DC.** Mitochondrial disease in man and mouse. *Scienc*1999; 283(5407): 1482– 8.
- Weidemann F, Breunig F, Beer M, et al.** Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. *Circulation* 2003; 108(11): 1299–301.
- Weng KP, Lin CC, Huang SH and Hsieh KS.** Idiopathic dilated cardiomyopathy in children: a single medical center's experience. *J. Chin. Med. Assoc* 2005; 68(8): 368-72
- Westerlind A, Wahlander H and Lindstedt G.** Clinical signs of heart failure are associated with increased levels of natriuretic peptide types B and A in children with congenital heart defects or cardiomyopathy. *Acta Paediatr.* 2004; 93: 340-345.
- Winter S, Jue K, Prochazka J, et al.** The role of l-carnitine in pediatric cardiomyopathy. *J Child Neurol* 1995; 10(Suppl. 2): S45– 51.
- Winter SC and Buist NR.** The role of Energy Metabolism Defects in Cardiomyopathy: From Inborn Errors to Ischemia: Cardiomyopathy in childhood, mitochondrial dysfunction, and the role of L-carnitine. *Am. Heart J* 2000; 139: 63-69.
- Winter SC, Szabo-Aczel S, Curry CJ, Hutchinson HT, Hogue R, Shug A.** Plasma carnitine deficiency: clinical observations in 51 pediatric patients. *Am J Dis Child* 1987; 141: 660-5.
- Wolter.** Carvedilol. Drug Facts and Comparison. Kluwer Health, Inc J 2004; 15(9): 1865-73.
- Wood MJ and Picard MH.** Utility of echocardiography in the evaluation of individuals with cardiomyopathy, *Heart* 2004; 90: 707-712.
- Wraith JE, Beck M, Lane R, et al.** Enzyme replacement therapy in Mucopolysaccharidosis I patients less than 5 years old: results of amultinational study of recombinant human α -L-Iduronidase (laronidase). *Pediatrics* in press.
- Wraith JE, Clarke LA, Beck M, et al.** Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). *J Pediatr* 2004; 144(5): 581–8.

References

Wraith JE. The first 5years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 2005; 6(3): 489–506.

Wynne J and Braunwald E. The cardiomyopathies. In "Braunwald Heart Disease: a Textbook of Cardiovascular Medicine. Zipes DP, Libby P, Bonow RO. et al . 7th edition. Elservier Inc 2005; 1659-16 96.

Yamaguchi S, Orii T, Suzuki Y, Maeda K, Oshima M, Hashimoto T. Newly identified forms of electron transfer flavoprotein deficiency in two patients with glutaric aciduria type II. Pediatr Res 1991; 29(1): 60 – 3.